Sort   by:  
 Page size 
UnknownMulticenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Not available
S-EPMC3641695 | biostudies-literature
UnknownThe novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
Not available
S-EPMC10845800 | biostudies-literature
UnknownAnalysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
Not available
S-EPMC4963453 | biostudies-literature
UnknownTumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.
Not available
S-EPMC8827906 | biostudies-literature
UnknownMammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
Not available
S-EPMC6318055 | biostudies-literature
UnknownTherapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.
Not available
S-EPMC8653766 | biostudies-literature
UnknownFOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Not available
S-EPMC5087040 | biostudies-literature
UnknownHyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
Not available
S-EPMC5960176 | biostudies-literature
UnknownPKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Not available
S-EPMC11443213 | biostudies-literature
UnknownHER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Not available
S-EPMC7850037 | biostudies-literature
Sort   by:  
 Page size